Reportstack has announced a new market research publication on PharmaSphere: Emerging Biotech Investment Report -Strategic Trends in Private Equity and Venture Capital Funding which provides in-depth analysis of the current trends and factors shaping the private equity and venture capital segments of the financial industry, bearing in mind that these are expected to have significant impact on the future of emerging biotechnology companies in the US and globally. Furthermore, the report identifies regions of the world that are attracting more investments in healthcare and discusses the various factors responsible for this trend. In addition, the report provides detailed profiles of 12 leading private equity firms, 15 top venture capital firms, and 15 US-based emerging biotechnology companies that completed initial public offerings in 2013.
Throughout the report, the analysts provide you with expert insight, expanding on each observation, strategy, and trend discussed, with the aim of providing you with the tools needed for making informed business decisions in the rapidly changing global investment landscape.
Scope
The report discusses a historical trend analysis of private equity and venture capital funding prior to- and after the financial market crash of 2008, including a change in the average value of completed deals in the healthcare industry
The report highlights how ongoing healthcare reform in parts of Europe and North America are resulting in a shift of deals activity involving private equity and venture capital firms to the Asia-Pacific
The report discusses the therapeutic areas attracting significant investments, as well as the factors responsible for such trends
The report provides detailed profiles of 12 leading private equity firms, 15 top venture capital firms, and 15 US-based emerging biotechnology companies that completed initial public offerings in 2013
The report includes a global strategic outlook on future trends that are expected in private equity and venture capital funding, as well as the need for a new financing model to drive the sustainable growth of emerging biotech companies
Throughout the report, the analysts provide you with expert insight, expanding on each observation, strategy, and trend discussed, with the aim of providing you with the tools needed for making informed business decisions in the rapidly changing global investment landscape.
Scope
The report discusses a historical trend analysis of private equity and venture capital funding prior to- and after the financial market crash of 2008, including a change in the average value of completed deals in the healthcare industry
The report highlights how ongoing healthcare reform in parts of Europe and North America are resulting in a shift of deals activity involving private equity and venture capital firms to the Asia-Pacific
The report discusses the therapeutic areas attracting significant investments, as well as the factors responsible for such trends
The report provides detailed profiles of 12 leading private equity firms, 15 top venture capital firms, and 15 US-based emerging biotechnology companies that completed initial public offerings in 2013
The report includes a global strategic outlook on future trends that are expected in private equity and venture capital funding, as well as the need for a new financing model to drive the sustainable growth of emerging biotech companies
To view the table of contents and know more details please visit PharmaSphere: Emerging Biotech Investment Report -Strategic Trends in Private Equity and Venture Capital Funding report.
No comments:
Post a Comment